LEUVEN, Belgium, Jan. 22, 2015 -- TiGenix NV , an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the European Patent Office has issued European Patent EP2292736 relating to an adipose-derived stem cell composition. The patent is entitled " Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue ".
http://ift.tt/1yS2IM9
http://ift.tt/1yS2IM9
No comments:
Post a Comment